We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

VEDA LAB

  Gold VEDALAB focuses on the development, production and marketing of in vitro immunodiagnostic reagents and instruments. I... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Regulatory and Other Rheumatoid Factors Analyzed in RA Patients

By LabMedica International staff writers
Posted on 06 Jan 2022
Print article
Image: The RF direct latex test for the detection of rheumatoid factor (RF) in serum (Photo courtesy of VedaLab)
Image: The RF direct latex test for the detection of rheumatoid factor (RF) in serum (Photo courtesy of VedaLab)
Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body.

Despite numerous studies, the only properties definitively established for rheumatoid factor (RF) are that RF is an antibody to the Fc portion of modified IgG, and that elevated RF levels are a diagnostic marker for RA. Both the mechanisms by which RF level is elevated in autoimmune and infectious diseases and the role that RF plays in healthy and disease states remain speculative.

Immunologists at the Udmurt State University (Izhevsk, Russian Federation) studied a total of 32 patients with an established diagnosis of rheumatoid arthritis. Of those, 22 patients had high to moderate rheumatoid arthritis activity. Several of the patients had systemic manifestations, such as anemia, rheumatoid nodules, Sjögren's syndrome. The duration of disease in the sample of RA patients studied was 2 to 20 years, with a mean of 8 ± 5.9 years and 35% of patients were receiving combination therapy.

The RF direct latex test (VedaLab, Alençon, France) was used to detect rheumatoid factor in the sera of arthritis patients. The regulatory rheumatoid factor (regRF) titer was determined in an agglutination test using human IgG-loaded tanned human erythrocytes. RegRF depletion from rheumatoid arthritis sera was also performed. Lyophilized human IgG was used to prepare an agglutination test system for detecting regRF. Size exclusion chromatography was performed using a Sephacryl S 100 26/400 column (Cytiva, Marlborough, MA, USA). A Genesys 10S UV-Vis Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) was used for the analysis.

The investigators reported that patients in remission had regRF levels higher than in healthy subjects. The regRF in remission was characterized by tight binding to its antigen, as in healthy subjects. The regRF levels in patients with active RA varied dramatically, and regRF binding to its antigen was weak. The exacerbation of Still's disease coincided with low regRF levels and affinity, while an improvement in patient condition was associated with an increase in regRF levels and affinity. The RF specific to RA, which was detected by the RF latex-fixation method, was a nonhomogeneous population of antibodies that included RF to lyophilized IgG, to IgG immobilized on polystyrene, and to rabbit IgG.

The authors concluded the RA remission is associated with an increase in regRF levels and affinity. Results of an analysis of a clinical case of Still's disease were consistent with the results obtained when patients with active rheumatoid arthritis were compared with those in remission. The study was published on December 24, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Udmurt State University
VedaLab
Cytiva
Thermo Fisher Scientific


Gold Supplier
Clinical Chemistry Reagents
SEKURE Clinical Chemistry Reagents
New
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8
New
Chemistry Analyzer
NB-201
New
Silver Supplier
Anti-Müllerian Hormone (AMH) ELISA Test
PCOCheck ELISA (CE)

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.